Publishing options:
Switzerland associated corresponding authors
Key information

1. How do we determine eligibility of the article for the Swiss agreement?

   • The submission date of the article should be on or after 1st January 2020
   • The corresponding author must be affiliated with a Swiss University
   • The article must be from an eligible journal

You can find all of this information on Elsevier agreements page:
https://www.elsevier.com/open-access/agreements/switzerland
2. What is the definition of the corresponding author for the purpose of the agreement?

- Corresponding author is the author who submits the article to Elsevier and stays in contact with Elsevier in the end-to-end journey.
- This is the author who makes the publishing choice on behalf of the author group.
- Every article has one corresponding author.
Key information

3. Role of the institutional librarian in the Elsevier OA Platform (EOAP)

- By the time the article in is your EOAP, we have published the first version of the article in ScienceDirect (within 48 hours of acceptance)

- The librarian therefore is not approving the publication of the article, but is validating whether the corresponding author can make use of the APC funds/discount as part of the agreement
IMPORTANT PLEASE TAKE ACTION, Production has begun on your article [JFUE_239019] in Fuel

Corresponding author receives an email post acceptance with a unique link to complete the author journey and choose publishing options.

We removed extra line breaks from this message.

Our reference: JFUE 239019
Article reference:
Article title:
To be published in: Fuel

Dear [Name],

Congratulations on your accepted paper! Thank you for choosing to publish in Fuel. Please read this e-mail carefully as it contains important information.

FINALIZE PUBLISHING YOUR ARTICLE:

We work hard to publish our authors' articles online as quickly and efficiently as possible; therefore processing of your accepted manuscript for publication has already begun. To ensure that we publish your article in accordance with your wishes, please now complete the following steps:

https://easychair.org

If this link does not work, please copy the entire URL (noting that it may run on to a second line in this message) into your browser. You should log in with your Elsevier Profile credentials, which you may have already created when submitting your article.

CHECK YOUR CONTACT DETAILS:

Please check that your details listed below are correct so we can contact you if needed:

Dr. [Name]
India
Phone: not available
Fax: not available
E-mail: [E-mail]
Author clicks on 
Complete the Rights and Access information form

Welcome Prof [Redacted],
To help us finalize the publication of your article please complete the publishing form(s) below.

Note: you will receive a confirmation e-mail after completing each form.

Information you may need to provide to complete the forms

Rights and Access

Complete the rights and access form

Help and Support

How you can share your article
Author rights information
A guide to publishing Open Access
Corresponding author selects his/her affiliation details which we use to identify the authors and match them to the Spanish agreement.
Corresponding author also adds the co-author affiliation details.
Author can add the Funder details. Funder can be the affiliated institute or a different one. In this case it is Milliman.
Publishing options is presented based on the details the author has entered. The author chooses Gold Open Access.
Select your user license

Please select your license. If you need to comply with a mandated license and the mandated license is not listed below, please visit our Support Hub for additional help.

- **CC BY 4.0**
  - [CC BY is the recommended choice of your institution](#)
  - A license to permit readers to share and adapt your article for any purpose, even commercially.
  - [Read more about CC BY 4.0](#)

- **CC BY-NC-ND 4.0**
  - A license to permit readers to share all or part of your article in any medium or format for non-commercial purposes.
  - Permission from Elsevier is required for the distribution of derivative versions of the article or for commercial use.
  - [Read more about CC BY-NC-ND 4.0](#)
Author selects the rights
System presents author with the Journal License Publishing Agreement

Your Status
- I am one author signing on behalf of all co-authors of the manuscript

License of Publishing Rights
I hereby grant to IAA an exclusive publishing and distribution license in the manuscript identified above and any tables, illustrations or other material submitted for publication as part of the manuscript (the "Article") in print, electronic and all other media (whether now known or later developed), in any form, in all languages, throughout the world, for the full term of copyright, and the right to license others to do the same, effective when the Article is accepted for publication. This license includes the right to enforce the rights granted herein against third parties. IAA

Supplemental Materials
'Supplemental Materials' shall mean materials published as a supplemental part of the Article, including but not limited to graphical, illustrative, video and audio material.

With respect to any Supplemental Materials that I submit, IAA shall have a perpetual worldwide non-exclusive right and license to publish, extract, reformat, adapt, build upon, index, redistribute, links to and otherwise use all or any part of the Supplemental Materials, in all forms and media (whether now known or later developed) and permit others to do so. The publisher shall apply the same and user license to the Supplemental Materials as to the Article where it publishes the Supplemental Materials with the Article in the journal on its online platforms on an Open Access basis.

Research Data
'Research Data' shall mean the result of observations or experimentation that validate research findings and that are published separate to the Article, which can include but are not limited to raw data, processed data, software, algorithms, protocols, and methods.

With respect to any Research Data that I wish to make accessible on a site or through a service of IAA, IAA shall have a perpetual worldwide, non-exclusive right and license to publish, extract, reformat, adapt, build upon, index, redistribute, links to and otherwise use all or any part of the
Authors agrees to the Journal License Publishing Agreement

- The Article and the Supplemental Materials do not infringe any copyright, violate any other intellectual property, privacy or other rights of any person or entity, or contain any libellous or other unlawful matter.

- I have obtained written permission from copyright owners for any excerpts from copyrighted works that are included and have credited the sources in the Article or the Supplemental Materials.

- Except as expressly set out in this License Agreement, the Article is not subject to any prior rights or licenses and, if my or any of my co-authors’ institution has a policy that might restrict my ability to grant the rights required by this License Agreement (taking into account the Scholarly communication rights permitted hereunder), a written waiver of that policy has been obtained.

- If I and/or any of my co-authors reside in Iran, Cuba, Sudan, Burma, Syria, or Crimea, the Article has been prepared in a personal, academic or research capacity and not as an official representative or otherwise on behalf of the relevant government or institution.

- If I am using any personal details or images of patients, research subjects or other individuals, I have obtained all consents required by applicable law and complied with the publisher’s policies relating to the use of such images or personal information. See https://www.elsevier.com/about/our-business/policies/patient-consent for further information.

- Any software contained in the Supplemental Materials is free from viruses, contaminants or worms.

- If the Article or any of the Supplemental Materials were prepared jointly with other authors, I have informed the co-author(s) of the terms of this License Agreement and that I am signing on their behalf as their agent, and I am authorized to do so.

Governing Law and Jurisdiction

This License Agreement will be governed by and construed in accordance with the laws of the country or state of Elsevier Ltd (“the Governing State”), without regard to conflict of law principles, and the parties irrevocably consent to the exclusive jurisdiction of the courts of the Governing State.

For information on the publisher’s copyright and access policies, please see http://www.elsevier.com/copyright.

☐ I have read and agree to the terms of the License Agreement.

19 December 2019

T-copyright license-v5/2017

Previous  Accept Agreement
This is the summary page explaining the choices the author made in the publishing journey.

Corresponding author and coauthors receive a copy of summary via email.

Articles become OA on Science Direct within 24 hours.

Librarian at the institute will receive a notification for validation within 48 hours who then has 3 weeks to complete the validation.

Review Order

- Publishing Option: Gold Open Access
- User License: CC BY 4.0
- Publishing Agreement:
  
  I am one author signing on behalf of all co-authors of the manuscript.

  I may share my final published article widely in accordance with the user License that I have selected.

  Further details on Elsevier Sharing Policy here.

Total payment due

Price (excluding taxes)

EUR 2,690.00

Institutional Agreement Discount

- 2,690.00

To pay (on validation)

0.00

If your institution cannot confirm your affiliation, you will receive a full price invoice for EUR 2,690.00 (ex. VAT). Within 2 weeks of receiving an invoice, you may contact Researcher Support to publish free of charge under the Subscription model.

Swiss Institutions and Elsevier Agreement
Support for authors and librarians

- Author queries – support@elsevier.com

- Librarian queries, EOAP account set up or changes – agreementactivation@elsevier.com

- Author journey videos:
  https://service.elsevier.com/app/answers/detail/a_id/29789/supporthub/publishing/track/APN2ZgoIDv8a~RNiGvwa~yKgpv0qOS75Mv9e~zj~PP_X/
Thank you